<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867551</url>
  </required_header>
  <id_info>
    <org_study_id>KDT1202A</org_study_id>
    <nct_id>NCT04867551</nct_id>
  </id_info>
  <brief_title>A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease</brief_title>
  <official_title>A Phase II Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study is to investigate the safety, pharmacokinetics and efficacy of&#xD;
      KDT-3594 in patients with early Parkinson's disease without a concomitant medication of&#xD;
      L-dopa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>The numbers of events and subjects, the incidence regarding adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of KDT-3594 and its metabolites</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plasma concentrations of KDT-3594 and its metabolites during treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline (Week 0) in MDS-UPDRS total score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>KDT-3594</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KDT-3594</intervention_name>
    <description>oral administration, dose titration</description>
    <arm_group_label>KDT-3594</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese patients&#xD;
&#xD;
          -  Patients who are diagnosed with Parkinson's disease according to UK Parkinson's&#xD;
             Disease society brain bank clinical diagnostic criteria&#xD;
&#xD;
          -  Patients with Parkinson's disease in Stages 1 to 3 on the Modified Hoehn and Yahr&#xD;
             Scale&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are suspected any parkinsonism except for idiopathic Parkinson's disease.&#xD;
&#xD;
          -  Patients who underwent neurosurgical treatment (stereotaxic destruction, deep brain&#xD;
             stimulation etc.) for PD, or patients for whom surgical treatment is scheduled during&#xD;
             the study&#xD;
&#xD;
          -  Patients with a complication of obvious dementia, or patients with Mini-Mental State&#xD;
             Examination (MMSE) score &lt; 24 points&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Koshihara</last_name>
    <role>Study Director</role>
    <affiliation>Kissei Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

